Human Microbiome Market

Human Microbiome Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032
Frequently asked questions about this report

The human microbiome market was estimated to be US$ 391.69 Million in 2022 and is expected to reach US$ 6582.26 Million by 2032.

The human microbiome market is expected to grow at a CAGR of 32.6% from 2023 to 2032.

The global human microbiome market is being driven by several major factors including the prevalence of chronic diseases and growing interest in personalized medicine rising awareness about the importance of the microbiome in maintaining human health.

North America is the largest market for human microbiome, accounting for a significant share of the global market. The growth in this region is primarily driven by the high prevalence of chronic diseases, growing research activities, and the presence of major players in the region.

Probiotics segment is the largest in the human microbiome market. Probiotics are widely used to maintain gut health and prevent and treat various gastrointestinal disorders, such as irritable bowel syndrome, inflammatory bowel disease, and antibiotic-associated diarrhea.

The United States is the largest contributor to the North American market due to the increasing awareness about the importance of microbiome in maintaining human health and the presence of several leading microbiome companies in the region.

4D Pharma plc, Enterome, Evelo Biosciences, Finch Therapeutics, Ferring Pharmaceuticals, Immuron Limited, Johnson & Johnson, LNC Therapeutics, Microbiome Therapeutics LLC, Osel, Inc., Pfizer Inc., Rebiotix Inc., Seres Therapeutics Inc., Synlogic, Inc., Vedanta Biosciences, Inc. among others, are the key players in this market.